EYPT

EyePoint is not an operating business you can value on its numbers — it is a single-catalyst clinical-stage biopharma. The income statement makes that plain: revenue fell -27.5% to $31.4M (its legacy ILUVIEN/YUTIQ franchise, now shrinking, not growing), while R&D jumped +66.3% to $221M to fund the DURAVYU Phase 3 program. The result is a -$232M net loss, a -776% operating margin, and a -75.8% ROE. The 37.5x P/S is meaningless here; the stock is a pure option on DURAVYU, whose LUGANO/LUCIA wet-AMD pivotal data the MD&A says is 'expected beginning in mid-2026' — i.e., effectively now. That is a coin-flip event, and the provided data gives no way to handicap it.

The more pressing, quantifiable problem is the cash runway. Operating cash flow was -$240M in FY2025, yet cash ended at just $102M — and that is *after* the October 2025 raise that netted ~$162M (11M shares plus over-allotment at $12.00). In other words, the company burned more than it raised and exited the year with well under six months of cash at the current burn. Shares outstanding already grew +21.4% year-over-year, accumulated deficit sits at -$1.10B, and another dilutive raise is all but certain into or around the very data readout investors are betting on — a structurally bad setup for existing holders.